Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Post by Lowpatch77on May 26, 2011 11:40am

473 Views

Post# 18628793

Hi everyone

New to the board, but following gpd for about a year off and on. Was looking to take a position after the last set of results, and thought I missed the boat when I got the alert for todays release, but there was no excitment and decided to get in regardless.
We have a winner here

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload